undamentalytics Newsletter
Sign in

Acadia Pharmaceuticals Inc (ACAD) stock

Add to watchlist

Add holding +

NASDAQ: ACAD Nasdaq Biotechnology Next results ~November 4, 2026

B+ Fundamentals grade

Acadia Pharmaceuticals Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$20

Valuation models combined (3)

Base case. Range ~$11–$25. Weighted average of 3 models (growth cash-flow model, forward price-to-earnings vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Acadia Pharmaceuticals Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 6 selling0 purchases and 25 sales by directors and officers, last 12 monthsInsider trades
  • Funds176 adding, 147 cuttingOf 56 active managers that changed their stake, 27 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Acadia Pharmaceuticals files

Where Acadia Pharmaceuticals stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.14bn, up 11.8% on a year earlier, faster than the 9.9% growth a quarter earlier. Free-cash-flow margin fell to 12.8% from 18.4% a year earlier. Operating margin narrowed to 7.6% from 23.2%. The diluted share count is up 3.0% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 2 financial-health checks. Our valuation models combined value is $23.27 a share, against a share price of $19.62.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Acadia Pharmaceuticals Inc's trailing-twelve-month revenue grew 11.8% year on year, with a free-cash-flow margin of 12.8%. Where it stands out: net margin of 33.4% ranks 14 of 180 biotechnology companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 22.2% while net income grew 71.3%: a 93pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.4bn.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 7.7% over 90 days.

Things to watch

  • Margins narrowing. Operating margin is down 15.7 points on a year ago.
  • Share dilution. Diluted shares rose 3.0% in a year.
  • Weak cash conversion. Free cash flow was 38% of net income over the last 12 months.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$0.18 against an average estimate of $0.04: beat by 317.2%
Revenue
$308m, up 16.4% on a year earlier
Share reaction
+12.5% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Guidance given
total revenues $1.24bn to $1.3bn (full year 2026); NUPLAZID net product sales $760m to $790m (full year 2026)
Next report
November 4, 2026; average EPS estimate $0.18

Acadia Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.6%
  • 1 week+3.7%
  • 1 month+2.6%
  • This year-23.4%
  • 1 year-9.8%
  • 5 years+0.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.1B
Operating margin
7.6%
Net margin
33.4%
EPS (TTM, diluted)
$2.21

Growth

Revenue growth
+11.8%
Change in growth rate
+1.8 pts
Share count change
+3.0%

Cash

Free cash flow (TTM)
$146M
FCF margin
12.8%
Stock pay % of revenue
5.1%

Earnings

Last results
August 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results
  3. Announcement
  4. Results
  5. Announcement
  6. Announcement
  7. Announcement
  8. Results
  9. Guidance
  10. Regulatory
  11. Results
  12. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Acadia Pharmaceuticals Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Acadia Pharmaceuticals Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.11 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$22 ~$17–$27 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$11 ~$10–$22 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$2.7 ~$1.7–$4.3 Left out: out of range vs price (0.13x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$0.4 ~$0.3–$0.4 Left out: out of range vs price (0.02x)
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: earnings are positive: price-to-earnings is the better measure
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$25 ~$21–$30 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$20 ~$11–$25 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Acadia Pharmaceuticals Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$35.65$28.84$30.11$16.17$42.78$53.46$23.34$15.92$31.31$18.35$26.71$20.47
Market value$3.6bn$3.3bn$3.7bn$2.0bn$6.3bn$8.4bn$3.7bn$2.6bn$5.1bn$3.1bn$4.5bn$3.5bn
+ Net debt (− = net cash)−$102m−$164m−$69m−$135m−$190m−$326m−$147m−$115m−$189m−$320m−$178m−$385m
Enterprise value$3.5bn$3.2bn$3.6bn$1.9bn$6.1bn$8.1bn$3.6bn$2.5bn$4.9bn$2.7bn$4.4bn$3.1bn
Multiples
Price / sales n/m192.8x29.6x9.1x18.6x19.0x7.7x5.0x7.1x3.2x4.2x3.1x
Price / earnings —————————13.5x11.6x9.3x
Price / free cash flow ————————n/m19.4x43.2x24.2x
EV / EBITDA —————————11.8x41.3x35.9x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

44 /100

Weak moat

How hard Acadia Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 18 / 20

    Cash operating profit has been a median 13.8% of total assets over 10 years.

  • Pricing power 19 / 20

    Gross margin has been a median 94.8%, moving by 3.1 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -48.6%; its worst year was -488.0%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 10 years, at a median -58.4% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 38.8% over five years; stock-based pay has been a median 14.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (49 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $333m and EPS of $0.18 (range $0.11 to $0.29) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.60 −28% $1.3bn +19%
Next $0.92 +55% $1.4bn +12%

Next year's EPS estimate has moved +7.7% in 90 days, across 13 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +62.3% on 90 days ago. In the last 30 days, 13 analysts raised Acadia Pharmaceuticals Inc's forecast and 0 cut it.

Consensus EPS forecast Acadia Pharmaceuticals Inc, last 90 days
$0.20 $0.40 $0.60 $0.80 $1.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.37 Current fiscal year, 60 days ago: $0.60 Current fiscal year, 30 days ago: $0.60 Current fiscal year, 7 days ago: $0.60 Current fiscal year, Now: $0.60 $0.60 Next fiscal year, 90 days ago: $0.85 Next fiscal year, 60 days ago: $0.89 Next fiscal year, 30 days ago: $0.90 Next fiscal year, 7 days ago: $0.92 Next fiscal year, Now: $0.92 $0.92

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.37$0.85
60 days ago $0.60$0.89
30 days ago $0.60$0.90
7 days ago $0.60$0.92
Now $0.60$0.92

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.04 $0.18 +317.2%
Mar 2026 $0.08 $0.02 −75.2%
Dec 2025 $0.14 $0.14 −4.2%
Sept 2025 $0.15 $0.42 +189.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 4, 2026
  • Total revenues full year 2026 $1.24bn to $1.3bn GAAP Raised
    “Total revenues revised to a range of $1.24 to $1.30 billion, up from the previous range of $1.22 to $1.28 billion.” source
  • NUPLAZID net product sales full year 2026 $760m to $790m GAAP Maintained
    “Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed NUPLAZID guidance of $760 to $790 million” source
  • DAYBUE global net product sales full year 2026 $480m to $510m GAAP Raised
    “DAYBUE (including all forms of trofinetide) global net product sales in the range of $480 to $510 million, up from the previous range of $460 to $490 million.” source
  • R&D expense full year 2026 $355m to $380m GAAP Lowered
    “R&D expense in the range of $355 to $380 million, down from the previous range of $385 to $410 million.” source
  • SG&A expense full year 2026 $660m to $700m GAAP
    “SG&A expense in the range of $660 to $700 million.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

20 analysts, Nov 2026
Buy1470%
Hold525%
Sell15%

Monthly trend

  1. Nov 2026410520
  2. Oct 2026411420
  3. Sep 2026412421

Counts of recommendations published by analysts covering Acadia Pharmaceuticals Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.3%
of tradable shares
Days to cover
3.81
at average volume
Short interest, 1 month
−6%
to October 15, 2026
Held by institutions
100%
of shares
Held by insiders
0.3%
of shares
Employees
796
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −9.8%

$22.70 on October 31, 2025 to $20.47

ThenNowEffect
Revenue (last 12 months) $1.0bn $1.1bn +11.8%
Net margin 21.8% 33.4% +53.3%
P/E multiple 17.1x 9.3x −45.8%
Share count 167m 172m −2.9%

Biggest factor: p/e multiple.

Last 3 years −15.0%

$24.07 on November 3, 2023 to $20.47

ThenNowEffect
Revenue (last 12 months) $551m $1.1bn +106.7%
P/S multiple 7.1x 3.1x −56.4%
Share count 163m 172m −5.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ACAD−56%−32%+97%−41%+46%−23%
Industry peers (median)−35%−57%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ACAD50%33%67%33%67%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ACAD−71%−53%−38%−54%−31%−39%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 77% from July 7, 2020 to June 21, 2022. Getting back needed a 338% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$18.62 – $30.57
From 52-week high
−33.0%
vs 50-day average
−13.1%
vs 200-day average
−13.4%
Volatility (1 year)
39%
Beta vs S&P 500
0.69

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±7.4%
After a week
6 up, 6 down
typical move ±9.4%
After a month
5 up, 7 down
typical move ±17.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +12.5% +1.6% +14.8% +13.0%
May 6, 2026 +0.9% +1.1% −0.8% −3.5%
February 25, 2026 +0.2% +0.3% −4.9% −12.7%
January 13, 2026 +1.0% −0.7% +0.6% −18.7%
November 5, 2025 −0.9% −0.7% +10.4% +25.6%
August 6, 2025 +3.2% +0.7% +6.3% +6.9%
May 7, 2025 +16.4% +1.1% +18.0% +51.2%
February 26, 2025 +1.7% −1.5% −4.9% −9.6%
November 6, 2024 +14.7% +3.3% +17.3% +15.2%
August 6, 2024 −17.6% +0.2% −14.6% −11.9%
May 8, 2024 −11.8% +0.6% −12.3% −13.7%
February 27, 2024 −8.3% +0.1% −8.1% −29.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Acadia Pharmaceuticals Inc in five measures

Fundamentals grade B+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Acadia Pharmaceuticals Inc
$600M $800M $1B $1.2B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $631.9M Revenue (TTM), FY23 Q4: $726.4M Revenue (TTM), FY24 Q1: $813.8M Revenue (TTM), FY24 Q2: $890.5M Revenue (TTM), FY24 Q3: $929.2M Revenue (TTM), FY24 Q4: $957.8M Revenue (TTM), FY25 Q1: $996.3M Revenue (TTM), FY25 Q2: $1B Revenue (TTM), FY25 Q3: $1B Revenue (TTM), FY25 Q4: $1.1B Revenue (TTM), FY26 Q1: $1.1B Revenue (TTM), FY26 Q2: $1.1B $1.1B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $631.9M
FY23 Q4 $726.4M
FY24 Q1 $813.8M
FY24 Q2 $890.5M
FY24 Q3 $929.2M
FY24 Q4 $957.8M
FY25 Q1 $996.3M
FY25 Q2 $1B
FY25 Q3 $1B
FY25 Q4 $1.1B
FY26 Q1 $1.1B
FY26 Q2 $1.1B
Revenue growth, TTM YoY Acadia Pharmaceuticals Inc
0% 20% 40% 60% 80% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 23.5% Revenue growth, TTM YoY, FY23 Q4: 40.4% Revenue growth, TTM YoY, FY24 Q1: 56.4% Revenue growth, TTM YoY, FY24 Q2: 61.7% Revenue growth, TTM YoY, FY24 Q3: 47.1% Revenue growth, TTM YoY, FY24 Q4: 31.8% Revenue growth, TTM YoY, FY25 Q1: 22.4% Revenue growth, TTM YoY, FY25 Q2: 14.4% Revenue growth, TTM YoY, FY25 Q3: 12.7% Revenue growth, TTM YoY, FY25 Q4: 11.9% Revenue growth, TTM YoY, FY26 Q1: 9.9% Revenue growth, TTM YoY, FY26 Q2: 11.8% 11.8%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 23.5%
FY23 Q4 40.4%
FY24 Q1 56.4%
FY24 Q2 61.7%
FY24 Q3 47.1%
FY24 Q4 31.8%
FY25 Q1 22.4%
FY25 Q2 14.4%
FY25 Q3 12.7%
FY25 Q4 11.9%
FY26 Q1 9.9%
FY26 Q2 11.8%
Operating margin (TTM) Acadia Pharmaceuticals Inc
-40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -24.4% Operating margin (TTM), FY23 Q4: -10.1% Operating margin (TTM), FY24 Q1: -0.6% Operating margin (TTM), FY24 Q2: 2.6% Operating margin (TTM), FY24 Q3: 12.1% Operating margin (TTM), FY24 Q4: 24.1% Operating margin (TTM), FY25 Q1: 23.6% Operating margin (TTM), FY25 Q2: 23.2% Operating margin (TTM), FY25 Q3: 23.0% Operating margin (TTM), FY25 Q4: 9.8% Operating margin (TTM), FY26 Q1: 7.4% Operating margin (TTM), FY26 Q2: 7.6% 7.6%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -24.4%
FY23 Q4 -10.1%
FY24 Q1 -0.6%
FY24 Q2 2.6%
FY24 Q3 12.1%
FY24 Q4 24.1%
FY25 Q1 23.6%
FY25 Q2 23.2%
FY25 Q3 23.0%
FY25 Q4 9.8%
FY26 Q1 7.4%
FY26 Q2 7.6%
FCF margin (TTM) Acadia Pharmaceuticals Inc
-40% -20% 0% 20% FY21 Q2 FY22 Q1 FY22 Q4 FY26 Q2 FCF margin (TTM), FY21 Q2: -30.3% FCF margin (TTM), FY21 Q3: -28.1% FCF margin (TTM), FY21 Q4: -26.2% FCF margin (TTM), FY22 Q1: -28.8% FCF margin (TTM), FY22 Q2: -25.3% FCF margin (TTM), FY22 Q3: -22.2% FCF margin (TTM), FY22 Q4: -22.0% FCF margin (TTM), FY25 Q2: 18.4% FCF margin (TTM), FY25 Q3: 18.9% FCF margin (TTM), FY25 Q4: 9.8% FCF margin (TTM), FY26 Q1: 10.4% FCF margin (TTM), FY26 Q2: 12.8% 12.8%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY21 Q2 -30.3%
FY21 Q3 -28.1%
FY21 Q4 -26.2%
FY22 Q1 -28.8%
FY22 Q2 -25.3%
FY22 Q3 -22.2%
FY22 Q4 -22.0%
FY25 Q2 18.4%
FY25 Q3 18.9%
FY25 Q4 9.8%
FY26 Q1 10.4%
FY26 Q2 12.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 6 42 2 5 1 0 0 17 125 224 339 442 484 517 726 958 1,072 1,139
Gross profit — — — — — — — 14 116 211 328 432 473 507 685 876 983 1,038
EBITDA −44 16 −23 −21 −38 −93 −164 −272 −291 −246 −245 −285 −168 −222 −72 232 106 88
Operating income −45 15 −23 −21 −38 −93 −165 −273 −292 −247 −247 −287 −170 −224 −73 231 105 86
Net income −45 15 −23 −21 −38 −92 −164 −271 −289 −245 −235 −282 −168 −216 −61 226 391 380
Diluted EPS −$1.20 $0.39 −$0.44 −$0.38 −$0.44 −$0.95 −$1.63 −$2.34 −$2.36 −$1.94 −$1.60 −$1.79 −$1.05 −$1.34 −$0.37 $1.36 $2.30 $2.21
Growth (year on year)
Revenue — +558.5% −95.1% +137.4% −76.7% −89.5% −49.2% +>999% +620.7% +79.2% +51.5% +30.3% +9.6% +6.8% +40.4% +31.8% +11.9% +11.8%
EBITDA — — −243.7% — — — — — — — — — — — — — −54.4% −63.2%
Operating income — — −251.4% — — — — — — — — — — — — — −54.6% −63.5%
Net income — — −250.4% — — — — — — — — — — — — — +72.7% +71.3%
Diluted EPS — — −212.8% — — — — — — — — — — — — — +69.1% +66.3%
Margins
Gross margin — — — — — — — 82.2% 92.7% 94.5% 96.7% 97.7% 97.8% 98.0% 94.3% 91.5% 91.7% 91.1%
EBITDA margin −693.2% 37.3% <−999% −423.4% <−999% <−999% <−999% <−999% −233.1% −109.9% −72.3% −64.5% −34.7% −42.8% −9.9% 24.2% 9.9% 7.7%
Operating margin −710.5% 35.8% <−999% −425.6% <−999% <−999% <−999% <−999% −234.1% −110.6% −72.7% −64.9% −35.2% −43.2% −10.1% 24.1% 9.8% 7.6%
Net margin −705.5% 35.9% <−999% −424.9% <−999% <−999% <−999% <−999% −231.7% −109.6% −69.4% −63.7% −34.7% −41.8% −8.4% 23.6% 36.5% 33.4%
Free-cash-flow margin — — −962.7% — <−999% <−999% <−999% <−999% −175.0% −75.8% −44.9% −32.5% −26.2% −22.0% 2.3% 16.4% 9.8% 12.8%
Cash flow
Cash from operations −14 −11 −20 −22 −32 −66 −122 −208 −218 −167 −151 −136 −126 −114 17 158 110 160
Capital spending — — 0 — 1 0 2 2 1 2 1 8 1 0 0 1 5 15
Free cash flow — — −20 — −32 −67 −124 −210 −219 −170 −152 −144 −127 −114 17 157 105 146
Stock-based pay 2 2 2 2 6 16 40 55 76 82 82 84 64 68 66 67 52 58
Free cash flow after stock pay — — −21 — −38 −83 −164 −265 −294 −251 −235 −228 −190 −182 −50 90 53 88
Balance sheet
Cash 18 7 7 58 12 62 102 164 69 135 190 326 147 115 189 320 178 385
Total debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −18 −7 −7 −58 −12 −62 −102 −164 −69 −135 −190 −326 −147 −115 −189 −320 −178 −385
Diluted shares 37m 39m 52m 55m 86m 97m 101m 116m 123m 127m 147m 157m 160m 162m 164m 166m 170m 172m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $1.7bn
Short-term assets $1.2bnLonger-term assets $518m
What it owes, and who funded it · $1.7bn
Short-term liabilities $361mLonger-term liabilities $75mShareholders' equity $1.3bn
  • Short-term assets cover short-term liabilities $1.2bn of assets due within a year against $361m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.2bn short-term assets against $75m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Acadia Pharmaceuticals Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+3.0%
year over year
R&D spending
29.1%
of revenue
Sales & admin spending
54.5%
of revenue
Days sales outstanding
48 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ACAD PTCT LKFT LEGN MDGL KNSA Median
Revenue, last 12 months $1.1bn $1.2bn $1.3bn $1.0bn $1.3bn $946m $56m
Revenue growth, last 12 months 11.8% −35.1% 321.6% 64.0% 149.0% 58.2% 12.6%
Revenue growth, 3-year average 27.4% 13.1% — — — 56.1% 13.7%
Revenue growth, latest quarter 16.4% 69.6% — — 71.2% 58.1% 10.2%
Gross margin 91.1% 96.0% 97.3% 61.4% — 90.2% 82.9%
Operating margin 7.6% 12.8% 26.5% −13.3% −25.1% 13.8% −189.4%
Operating margin, 3-year average 11.1% 13.8% −39.1% — <−999% 4.4% −363.5%
Net margin 33.4% −9.2% 28.9% −28.8% −25.3% 11.6% −169.8%
Cash from operations / revenue 14.1% 0.9% −23.1% −9.7% −15.4% 21.0% −168.0%
Free-cash-flow margin 12.8% 0.2% −24.4% −12.5% −16.1% 20.8% −162.4%
Free-cash-flow margin, 3-year average 0.8% 6.4% −127.4% — <−999% 13.6% −310.0%
Stock pay / revenue 5.1% 7.7% 2.2% — 9.5% 4.8% 20.0%
Change in share count 3.0% 9.3% 0.0% 0.8% 14.8% 8.5% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 11.8% 12.6% 87 of 172
Change in growth rate Growth +1.8pp -0.1pp 71 of 172
Gross margin Profitability 91.1% 82.4% 19 of 75
Operating margin Profitability 7.6% -189.4% 31 of 175
Net margin Profitability 33.4% -157.3% 14 of 180
Free-cash-flow margin Cash generation 12.8% -145.4% 31 of 176
Stock pay as % of revenue Cash generation 5.1% 19.2% 35 of 179
Change in share count Balance sheet 3.0% 7.9% 55 of 156
Days sales outstanding Balance sheet 48 days 75 days 27 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$4.3B
Institutions reporting
349
Shares held vs prior quarter
▲ 2.2%
Positions opened / closed
42 / 35

Top buyers and sellers, Q2 2026: 176 institutions bought and 147 sold ; the biggest buyer was Marshall Wace, LLP (+1.7M shares) and the biggest seller First Trust Advisors LP (−3.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Baker Bros. Advisors LP $1.1B 42.9M 25.5% 0.0%
Blackrock, Inc. $570M 22.5M 13.4% ▲ 4.5%
State Street Corp $230M 9.1M 5.4% ▲ 8.9%
Vanguard Portfolio Management LLC $224M 8.8M 5.2% ▲ 1.9%
RTW Investments, LP $181M 7.1M 4.2% 0.0%
Vanguard Capital Management LLC $146M 5.8M 3.4% ▲ 1.8%
Dimensional Fund Advisors LP $93.5M 3.7M 2.2% ▲ 17.1%
Geode Capital Management, LLC $85M 3.4M 2.0% ▼ 3.1%
Palo Alto Investors LP $72.5M 2.9M 1.7% ▼ 0.3%
Goldman Sachs Group Inc $65.3M 2.6M 1.5% ▲ 65.6%
Qube Research & Technologies Ltd $61.9M 2.4M 1.5% ▲ 157.5%
Point72 Asset Management, L.P. $61.6M 2.4M 1.4% ▼ 5.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Acadia Pharmaceuticals Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $3.5M 25 trades by 6 insiders · 77% under pre-set plans
Net ▼ $3.5M net selling
Insider Date Trade Shares Price Value
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER October 30, 2026 Sell pre-set plan 3,321 $20.88 $69,342
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER August 6, 2026 Sell pre-set plan 9,292 $29.34 $272,627
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER August 6, 2026 Sell pre-set plan 5,000 $29.00 $145,000
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER August 5, 2026 Sell pre-set plan 5,849 $29.00 $169,621
Thompson Elizabeth H.Z. EVP, Head of Research & Dev July 30, 2026 Sell pre-set plan 16,508 $26.13 $431,354
Thompson Elizabeth H.Z. EVP, Head of Research & Dev July 30, 2026 Sell pre-set plan 50 $26.17 $1,308
Kihara James PRINCIPAL ACCOUNTING OFFICER June 26, 2026 Sell pre-set plan 11,421 $26.08 $297,860
Kihara James PRINCIPAL ACCOUNTING OFFICER May 26, 2026 Sell 5,401 $21.18 $114,393
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER May 4, 2026 Sell pre-set plan 3,506 $21.79 $76,396
Kihara James PRINCIPAL ACCOUNTING OFFICER May 4, 2026 Sell pre-set plan 1,332 $21.79 $29,024
Kihara James PRINCIPAL ACCOUNTING OFFICER April 7, 2026 Sell pre-set plan 1,030 $22.20 $22,866
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER April 7, 2026 Sell pre-set plan 2,709 $22.20 $60,140

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 3 trades and filings

No trades in Acadia Pharmaceuticals Inc disclosed in the last 12 months; 3 earlier trades on record.

  • Chris Jacobs(R-NY 27):Sale (full), $1,001 - $15,000, traded June 16, 2022, filed July 28, 2022
  • Chris Jacobs(R-NY 27):Sale (partial), $1,001 - $15,000, traded September 8, 2020, filed November 6, 2020
  • Gilbert Ray Cisneros, Jr.(D-CA 39):Sale (full), $1,001 - $15,000, traded February 19, 2019, filed March 8, 2019

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 23, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 6, 2026
  • February 25, 2026
  • January 13, 2026
  • November 5, 2025
  • August 6, 2025

Recent SEC filings

Data status

When each part of this page on Acadia Pharmaceuticals Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Acadia Pharmaceuticals Inc in brief

What does Acadia Pharmaceuticals Inc do?
Acadia Pharmaceuticals Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Acadia Pharmaceuticals Inc's stock ticker?
Acadia Pharmaceuticals Inc trades under the ticker ACAD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Acadia Pharmaceuticals Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Acadia Pharmaceuticals Inc reported revenue of $1.1B, 11.8% higher than a year earlier, according to its SEC filings.
What is Acadia Pharmaceuticals Inc's free cash flow?
Acadia Pharmaceuticals Inc's free-cash-flow margin is 12.8% of revenue over the trailing twelve months, ranking 31 of the 176 biotechnology companies we cover.
Who are Acadia Pharmaceuticals Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Baker Bros. Advisors LP, Blackrock, Inc. and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Acadia Pharmaceuticals Inc's market cap?
On November 2, 2026, Acadia Pharmaceuticals Inc's market capitalisation was about $3.5B, with a price-to-earnings ratio of 9.3 and net debt of -$385M. Market figures come from third-party market data and may be delayed.
Who are Acadia Pharmaceuticals Inc's competitors?
In our Biotechnology peer group, the companies closest to Acadia Pharmaceuticals Inc are PTC Therapeutics, Inc., Lakefront Biotherapeutics NV, Legend Biotech Corp, Madrigal Pharmaceuticals, Inc. and Kiniksa Pharmaceuticals International, plc. The side-by-side comparison below sets their revenue, margins and growth against Acadia Pharmaceuticals Inc's.
Are insiders buying or selling Acadia Pharmaceuticals Inc stock?
Over the last 12 months, Acadia Pharmaceuticals Inc's directors and officers reported 0 open-market purchases and 25 sales on Form 4. The insider trading page charts every trade.
When is Acadia Pharmaceuticals Inc's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Acadia Pharmaceuticals Inc announces its own schedule.